Biopharmaceutical Manufacturing, Upstream, Downstream …
2025年1月9日 · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
Trends in biosimilars: Regulatory approvals in 2024
2024年7月24日 · The biosimilars market is rapidly growing as global demand for biosimilars continues to grow. The global biosimilar market is estimated to reach a size of $43.8 billion by the end of 2024, and to grow over $100 billion in the next 10 years.. Biologics are expensive medications, which is driving up the popularity of biosimilars as a more cost-effective alternative.
Bio developments - News - Biopharma-Reporter.com
2024年12月17日 · News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Bio developments - biopharma-reporter.com
2024年12月10日 · The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA approval in adults aged 18 to 59 who are at an increased risk of developing lower respiratory tract disease caused by RSV (RSV-LRTD).
Trends - biopharma-reporter.com
2024年11月14日 · News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Pipelines - biopharma-reporter.com
2024年12月3日 · Director of cell and gene therapy R&D at Lonza, this week's inspiring female is Inbar who we spoke to about her passion for discovering the future and mentor support sparked her early interest in biology and informed her journey of resiliency.
BioPharmaReporter gets a new look
2024年11月26日 · We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t change, but we’ve tweaked the look and feel of the site to bring you improved navigation, more content-rich articles, enhanced search capabilities and a better browsing experience.
nChroma Bio formed by merging genetic medicine companies
2024年12月12日 · Chroma Bio was launched in 2021 with $125 million in seed funding and aimed to take gene editing one step further by editing the epigenome, namely, markers on the genome that control the way genes are expressed in response to different stimuli.. Nvelop began in stealth mode in 2022, but officially launched earlier this year with $100 million in funding.
Biosimilar producer looking to get first to market advantage in …
2021年6月23日 · Bio-Thera Solutions recently initiated a Phase 3 trial of its proposed golimumab biosimilar BAT2506 in China and Eastern Europe, making it the first subcutaneous golimumab biosimilar to do so in multiple countries, according to a report from GlobalData.
Inflation law drives biologic drugs to outpace small molecules in …
2023年7月6日 · Biotechs located in the US received 19% or $7.6 billion more venture financing from 2018-2023 (YTD) for biologic innovator drugs compared to small molecule counterparts, driven by inflation law to drive down prescription drug prices, reveals GlobalData.